Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study.
Diabetes research and clinical practice（2022）
摘要
SGLT2i showed a significant reduction in FLI and its components. We suggest that SGLT2i may have beneficial effects in reducing the prevalence of NAFLD in type 2 diabetes.
更多查看译文
关键词
Dipeptidyl peptidase 4 inhibitors,Nonalcoholic fatty liver disease,Sodium-glucose cotransporter 2 inhibitors,Type 2 diabetes mellitus
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要